Albuminomics

Diabetes Mellitus

2 min read

Diabetes Mellitus

Relevance to this research

Diabetes is primarily relevant as a confounding comorbidity in HSA PTM profiling and as a future target disease for PTM-CQFD project.

  • Chronic hyperglycemia → elevated HSA glycation (HSA+GLYC, HSA+2GLYC, HSA+CYS+GLYC)
  • HbA1c (glycated hemoglobin) is the clinical standard for glycemic control; HSA glycation offers a shorter time-window (~2–3 weeks vs 3 months for HbA1c) — see Glycation
  • In the el-balkhi-2025 ALBOM cohort: diabetes prevalence varies by etiology (MASH cohort has highest comorbid diabetes burden); this is a potential confound for glycation-based isoforms

Comorbidity in CLD (MASH)

  • MASH (metabolic dysfunction-associated steatohepatitis) = liver disease driven by insulin resistance and metabolic syndrome
  • Diabetes is a key driver and complication of MASH → elevated HSA glycation in early CLD stages (F0/F1/F2) driven partly by diabetes burden, not only by hepatic stress

Future target (PTM-CQFD)

  • PTM-CQFD project targets NASH/NAFLD cohorts → overlaps heavily with diabetic populations
  • Longitudinal PTM evolution in patients with diabetes + NASH may be a key discriminator vs NASH without diabetes

Key connections

  • Glycation — primary PTM modification driven by hyperglycemia
  • HSA — carries glycation adducts; HSA glycation is more dynamic than HbA1c
  • Liver fibrosis — MASH is a major CLD etiology; diabetes is a driver

Graph View